Literature DB >> 15057311

VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.

Claus Cursiefen1, Lu Chen, Leonardo P Borges, David Jackson, Jingtai Cao, Czeslaw Radziejewski, Patricia A D'Amore, M Reza Dana, Stanley J Wiegand, J Wayne Streilein.   

Abstract

Lymphangiogenesis, an important initial step in tumor metastasis and transplant sensitization, is mediated by the action of VEGF-C and -D on VEGFR3. In contrast, VEGF-A binds VEGFR1 and VEGFR2 and is an essential hemangiogenic factor. We re-evaluated the potential role of VEGF-A in lymphangiogenesis using a novel model in which both lymphangiogenesis and hemangiogenesis are induced in the normally avascular cornea. Administration of VEGF Trap, a receptor-based fusion protein that binds and neutralizes VEGF-A but not VEGF-C or -D, completely inhibited both hemangiogenesis and the outgrowth of LYVE-1(+) lymphatic vessels following injury. Furthermore, both lymphangiogenesis and hemangiogenesis were significantly reduced in mice transgenic for VEGF-A(164/164) or VEGF-A(188/188) (each of which expresses only one of the three principle VEGF-A isoforms). Because VEGF-A is chemotactic for macrophages and we demonstrate here that macrophages in inflamed corneas release lymphangiogenic VEGF-C/VEGF-D, we evaluated the possibility that macrophage recruitment plays a role in VEGF-A-mediated lymphangiogenesis. Either systemic depletion of all bone marrow-derived cells (by irradiation) or local depletion of macrophages in the cornea (using clodronate liposomes) prior to injury significantly inhibited both hemangiogenesis and lymphangiogenesis. We conclude that VEGF-A recruitment of monocytes/macrophages plays a crucial role in inducing inflammatory neovascularization by supplying/amplifying signals essential for pathological hemangiogenesis and lymphangiogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057311      PMCID: PMC379325          DOI: 10.1172/JCI20465

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervival cancer.

Authors:  S F Schoppmann; M Schindl; S Breiteneder-Geleff; A Soleima; G Breitenecker; B Karner; P Birner
Journal:  Anticancer Res       Date:  2001 Sep-Oct       Impact factor: 2.480

2.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.

Authors:  B Berse; L F Brown; L Van de Water; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

3.  The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis.

Authors:  M Clauss; H Weich; G Breier; U Knies; W Röckl; J Waltenberger; W Risau
Journal:  J Biol Chem       Date:  1996-07-26       Impact factor: 5.157

4.  Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.

Authors:  M R Freeman; F X Schneck; M L Gagnon; C Corless; S Soker; K Niknejad; G E Peoples; M Klagsbrun
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

Review 5.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.

Authors:  N Van Rooijen; A Sanders
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

6.  Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate.

Authors:  G Van der Veen; L Broersma; C D Dijkstra; N Van Rooijen; G Van Rij; R Van der Gaag
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-08       Impact factor: 4.799

Review 7.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

8.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.

Authors:  B Barleon; S Sozzani; D Zhou; H A Weich; A Mantovani; D Marmé
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

9.  Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas.

Authors:  J W Streilein; D Bradley; Y Sano; Y Sonoda
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-02       Impact factor: 4.799

10.  The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences.

Authors:  D T Shima; M Kuroki; U Deutsch; Y S Ng; A P Adamis; P A D'Amore
Journal:  J Biol Chem       Date:  1996-02-16       Impact factor: 5.157

View more
  377 in total

1.  Mouse corneal lymphangiogenesis model.

Authors:  Renhai Cao; Sharon Lim; Hong Ji; Yin Zhang; Yunlong Yang; Jennifer Honek; Eva-Maria Hedlund; Yihai Cao
Journal:  Nat Protoc       Date:  2011-05-19       Impact factor: 13.491

2.  A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap.

Authors:  Jingtai Cao; Lian Zhao; Yiwen Li; Yang Liu; Weihong Xiao; Ying Song; Lingyu Luo; Deqiang Huang; George D Yancopoulos; Stanley J Wiegand; Rong Wen
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

3.  Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.

Authors:  Jeremy M Sivak; Allison C Ostriker; Amber Woolfenden; John Demirs; Rosemarie Cepeda; Debby Long; Karen Anderson; Bruce Jaffee
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

4.  Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas.

Authors:  Elena Gallego; Luis Vicioso; Martina Alvarez; Isabel Hierro; Lidia Pérez-Villa; Alfredo Blanes; Alfredo Matilla
Journal:  Virchows Arch       Date:  2011-01-29       Impact factor: 4.064

Review 5.  Head and neck lymphatic tumors and bony abnormalities: a clinical and molecular review.

Authors:  Karthik Balakrishnan; Mark Majesky; Jonathan A Perkins
Journal:  Lymphat Res Biol       Date:  2011       Impact factor: 2.589

6.  Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury.

Authors:  Jamie C Zampell; Sonia Elhadad; Tomer Avraham; Evan Weitman; Seth Aschen; Alan Yan; Babak J Mehrara
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

7.  Investigation of in vivo anti-inflammatory and anti-angiogenic attributes of coumarin-rich ethanolic extract of Melilotus indicus.

Authors:  Mohammad Saleem; Muhammad Asif; Anum Parveen; Hafiza Sidra Yaseen; Malik Saadullah; Asiya Bashir; Jawaria Asif; Mehwish Arif; Ikram Ullah Khan; Rizwan Ullah Khan
Journal:  Inflammopharmacology       Date:  2020-04-15       Impact factor: 4.473

8.  Blockade of angiopoietin-2/Tie2 signaling pathway specifically promotes inflammation-induced angiogenesis in mouse cornea.

Authors:  Zhi-Xin Yan; Yi Luo; Ning-Fei Liu
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

9.  Increased risk of recurrence associated with certain risk factors in breast cancer patients after DIEP-flap reconstruction and lipofilling-a matched cohort study with 200 patients.

Authors:  Sonia Fertsch; Mazen Hagouan; Beatrix Munder; Tino Schulz; Alina Abu-Ghazaleh; Julia Schaberick; Peter Stambera; Mohammed Aldeeri; Christoph Andree; Oliver Christian Thamm
Journal:  Gland Surg       Date:  2017-08

10.  Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1.

Authors:  Francesca Seta; Kiran Patil; Lars Bellner; Alexandre Mezentsev; Rowena Kemp; Michael W Dunn; Michal Laniado Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-05-21       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.